↓ Skip to main content

Multicentre randomized controlled trial comparing ferric(III)carboxymaltose infusion with oral iron supplementation in the treatment of preoperative anaemia in colorectal cancer patients

Overview of attention for article published in BMC Surgery, June 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
138 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Multicentre randomized controlled trial comparing ferric(III)carboxymaltose infusion with oral iron supplementation in the treatment of preoperative anaemia in colorectal cancer patients
Published in
BMC Surgery, June 2015
DOI 10.1186/s12893-015-0065-6
Pubmed ID
Authors

W. A. A. Borstlap, C. J. Buskens, K. M. A. J. Tytgat, J. B. Tuynman, E. C. J. Consten, R. C. Tolboom, G. Heuff, N. van Geloven, B. A. van Wagensveld, C. A. C.A. Wientjes, M. F. Gerhards, S. M. M. de Castro, J. Jansen, A. W. H. van der Ven, E. van der Zaag, J. M. Omloo, H. L. van Westreenen, D. C. Winter, R. P. Kennelly, M. G. W. Dijkgraaf, P. J. Tanis, W. A. Bemelman

Abstract

At least a third of patients with a colorectal carcinoma who are candidate for surgery, are anaemic preoperatively. Preoperative anaemia is associated with increased morbidity and mortality. In general practice, little attention is paid to these anaemic patients. Some will have oral iron prescribed others not. The waiting period prior to elective colorectal surgery could be used to optimize a patients' physiological status. The aim of this study is to determine the efficacy of preoperative intravenous iron supplementation in comparison with the standard preoperative oral supplementation in anaemic patients with colorectal cancer. In this multicentre randomized controlled trial, patients with an M0-staged colorectal carcinoma who are scheduled for curative resection and with a proven iron deficiency anaemia are eligible for inclusion. Main exclusion criteria are palliative surgery, metastatic disease, neoadjuvant chemoradiotherapy (5 × 5 Gy = no exclusion) and the use of Recombinant Human Erythropoietin within three months before inclusion or a blood transfusion within a month before inclusion. Primary endpoint is the percentage of patients that achieve normalisation of the haemoglobin level between the start of the treatment and the day of admission for surgery. This study is a superiority trial, hypothesizing a greater proportion of patients achieving the primary endpoint in favour of iron infusion compared to oral supplementation. A total of 198 patients will be randomized to either ferric(III)carboxymaltose infusion in the intervention arm or ferrofumarate in the control arm. This study will be performed in ten centres nationwide and one centre in Ireland. This is the first randomized controlled trial to determine the efficacy of preoperative iron supplementation in exclusively anaemic patients with a colorectal carcinoma. Our trial hypotheses a more profound haemoglobin increase with intravenous iron which may contribute to a superior optimisation of the patient's condition and possibly a decrease in postoperative morbidity. ClincalTrials.gov: NCT02243735 .

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 138 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 138 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 20 14%
Researcher 17 12%
Student > Bachelor 17 12%
Student > Ph. D. Student 14 10%
Other 11 8%
Other 36 26%
Unknown 23 17%
Readers by discipline Count As %
Medicine and Dentistry 70 51%
Nursing and Health Professions 17 12%
Agricultural and Biological Sciences 4 3%
Biochemistry, Genetics and Molecular Biology 3 2%
Sports and Recreations 3 2%
Other 14 10%
Unknown 27 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 July 2016.
All research outputs
#6,957,862
of 8,037,685 outputs
Outputs from BMC Surgery
#259
of 356 outputs
Outputs of similar age
#230,886
of 273,864 outputs
Outputs of similar age from BMC Surgery
#18
of 24 outputs
Altmetric has tracked 8,037,685 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 356 research outputs from this source. They receive a mean Attention Score of 2.5. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,864 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.